Cysteine

Cysteine

SCHEMBL888041

NC(CS)C(=O)O.OCC(O)CO

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.73
SLC7A11 Q9UPY5 1/20 0.73
LMNA P02545 2/20 0.46
SLC1A1 P43005 2/20 0.45
ENPEP Q07075 6/20 0.41
ALDH1A1 P00352 1/20 0.41
USP2 O75604 1/20 0.39
SLCO1B1 Q9Y6L6 1/20 0.39
OR51E2 Q9H255 1/20 0.39
GSR P00390 2/20 0.38
GRIK1 P39086 2/20 0.38
GRIK2 Q13002 2/20 0.38
GRM1 Q13255 2/20 0.38
GRM2 Q14416 2/20 0.38
SLC7A5 Q01650 1/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cysteine SCHEMBL888042 1.00 PTGS1 (0.73) PTGS1SLC7A11LMNASLC1A1ENPEP
Cysteine SCHEMBL3396295 0.93 PTGS1 (0.70) PTGS1SLC7A11LMNASLC1A1ENPEP
Cysteine SCHEMBL3396289 0.93 PTGS1 (0.70) PTGS1SLC7A11LMNASLC1A1ENPEP
Serine SCHEMBL26613653 0.86 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPALDH1A1
Serine SCHEMBL27748272 0.86 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPALDH1A1
Serine SCHEMBL1162414 0.86 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPALDH1A1
Serine SCHEMBL17113864 0.86 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPALDH1A1
Serine SCHEMBL1162408 0.86 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPALDH1A1
Serine SCHEMBL17113867 0.86 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPALDH1A1
Cysteine SCHEMBL1868335 0.85 PTGS1 (1.00) PTGS1SLC7A11SLC1A1ENPEPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8986700-B2 Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2015-03-24 US disclosed
EP-1546206-B1 Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitiopes QUEENSLAND INST MED RES (AU) 2014-12-17 EP disclosed
US-20110280899-A1 Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2011-11-17 US disclosed
EP-2314630-A1 Method of producing immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2011-04-27 EP disclosed
US-7833532-B2 Immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2010-11-16 US disclosed
EP-1546206-A4 NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND CYTOTOXIC T LYMPHOCYTE (CTL) EPITOPES QUEENSLAND INST MED RES (AU) 2007-10-10 EP disclosed
US-20070160631-A1 Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2007-07-12 US disclosed
EP-1546206-A1 NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND CYTOTOXIC T LYMPHOCYTE (CTL) EPITOPES THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2005-06-29 EP disclosed
WO-2004014957-A1 NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND CYTOTOXIC T LYMPHOCYTE (CTL) EPITOPES THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110280899-A1 Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes LTA, LY96, CD4 PTGS1 4001/4885SLC7A11 1346/4885LMNA 1433/4885
US-20070160631-A1 Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes LY96, LTA, CD4 PTGS1 4132/4885SLC7A11 1273/4885LMNA 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.